Treatment with GCV early after transplantation preserves alloengraftment and reduces GVHD
| Group . | Donor T cells added . | GCV . | Spleen . | Thymus size2-154(× 10−6) . | Percent CD4+8+thymocytes# . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Percent donor T cells* . | Percent CD3+TK+ T cells† . | Size‡ (× 10−6) . | B cells2-153 (× 10−6) . | Donor T cells2-155(× 10−6) . | |||||
| I | None | No | 26 ± 8 | 0 | 40 ± 4 | 9 ± 2 | ND | 66 ± 12 | 78 ± 4 |
| II | 5 × 105 TK+ | No | 98 ± 2 | 31 ± 6 | 11 ± 3 | 4 ± 2 | 3 ± 1 | 24 ± 12 | 31 ± 8 |
| III | 5 × 105 TK+ | Yes | 86 ± 6 | 10 ± 2 | 34 ± 5 | 20 ± 4 | 6 ± 1 | 85 ± 12 | 82 ± 2 |
| Group . | Donor T cells added . | GCV . | Spleen . | Thymus size2-154(× 10−6) . | Percent CD4+8+thymocytes# . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Percent donor T cells* . | Percent CD3+TK+ T cells† . | Size‡ (× 10−6) . | B cells2-153 (× 10−6) . | Donor T cells2-155(× 10−6) . | |||||
| I | None | No | 26 ± 8 | 0 | 40 ± 4 | 9 ± 2 | ND | 66 ± 12 | 78 ± 4 |
| II | 5 × 105 TK+ | No | 98 ± 2 | 31 ± 6 | 11 ± 3 | 4 ± 2 | 3 ± 1 | 24 ± 12 | 31 ± 8 |
| III | 5 × 105 TK+ | Yes | 86 ± 6 | 10 ± 2 | 34 ± 5 | 20 ± 4 | 6 ± 1 | 85 ± 12 | 82 ± 2 |
Irradiated (850 cGy) AKR mice (Thy1.1+) were transplanted with either TCD B6.PL (Thy1.1+) BM alone (107 cells) (group I) (N = 12/group) or together with 5 × 105 B6 (Thy 1.2+) TK+ T cells (groups II and III) (n = 13-19/group). Group III mice were treated with GCV (50 mg/kg) for 5 days beginning on day 4 after transplantation. Animals were sacrificed 26-33 days after BMT and analyzed for splenic and thymic reconstitution. Donor T cells were defined as H-2b+/CD3+ and transgenic TK+ T cells as Thy1.2+/CD3+. Data are presented as the mean ± SE.
Group I v III, P < .0002; II v III, P= .0018.
Group II v III, P < .001.
Group I v III, P = .43; II v III, P= .003.
Group I v II, P = .016; I v III, P = .04; II v III, P < .001.
Group II v III, P = .02.
Group I v III, P = .34; II v III, P = .001.
#Group I v III, P = .67; II v III, P < .001.